Quantitation of hematogones at the time of engraftment is a useful prognostic indicator in allogeneic hematopoietic stem cell transplantation

Blood

Volumn 121, Issue 5, 2013, Pages 840-848

  Shima, Takahiro ^a,b   Miyamoto, Toshihiro ^a   Kikushige, Yoshikane ^a,b   Mori, Yasuo ^a,b   Kamezaki, Kenjiro ^a   Takase, Ken ^c   Henzan, Hideho ^c   Numata, Akihiko ^c   Ito, Yoshikiyo ^d   Takenaka, Katsuto ^a   Iwasaki, Hiromi ^b   Kamimura, Tomohiko ^d   Eto, Tetsuya ^c   Nagafuji, Koji ^a   Teshima, Takanori ^b   Kato, Koji ^a   Akashi, Koichi ^a,b  

^a Department of Medicine and Biosystemic Science ^*  (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c HARASANSHIN HOSPITAL   (Japan)

^d HAMANOMACHI HOSPITAL   (Japan)

Author keywords

Quantitation of hematogones at engraftment is useful to predict prognosis of patients treated with allogeneic stem cell transplantation

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CANCER PROGNOSIS; CELL LINE; CONTROLLED STUDY; CORD BLOOD STEM CELL TRANSPLANTATION; DISEASE SEVERITY; ENGRAFTMENT; FEMALE; GRAFT RECIPIENT; GRAFT VERSUS HOST REACTION; HEMATOGONE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC CELL; HUMAN; HUMAN CELL; LEUKEMIA REMISSION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYELODYSPLASTIC SYNDROME; NONHODGKIN LYMPHOMA; ORGAN DONOR; OVERALL SURVIVAL; PRIORITY JOURNAL; QUANTITATIVE ASSAY; RECURRENCE FREE SURVIVAL; REDUCED INTENSITY CONDITIONING; UMBILICAL CORD BLOOD; WHOLE BODY RADIATION;

EID: 84873551222     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-409607     Document Type: Article

References (48)

1. McKenna RW, Washington LT, Aquino DB, Picker LJ, Kroft SH. Immunophenotypic analysis of hematogones (B-lymphocyte precursors) in 662 consecutive bone marrow specimens by 4-color flow cytometry. Blood. 2001;98(8):2498-2507.
2. Sevilla DW, Colovai AI, Emmons FN, Bhagat G, Alobeid B. Hematogones: a review and update. Leuk Lymphoma. 2010;51(1):10-19.
3. Muehleck SD, McKenna RW, Gale PF, Brunning RD. Terminal deoxynucleotidyl transferase (TdT)-positive cells in bone marrow in the absence of hematologic malignancy. Am J Clin Pathol. 1983;79(3):277-284. (Pubitemid 13164105)
4. Davis RE, Longacre TA, Cornbleet PJ. Hematogones in the bone marrow of adults. Immunophenotypic features, clinical settings, and differential diagnosis. Am J Clin Pathol. 1994;102(2):202-211. (Pubitemid 24320526)
5. Chantepie SP, Salaun V, Parienti JJ, et al. Hematogones: a new prognostic factor for acute myeloblastic leukemia. Blood. 2011;117(4):1315-1318.
6. Honebrink T, Dayton V, Burke MJ, et al. Impact of bone marrow hematogones on umbilical cord blood transplantation outcomes in patients with acute myeloid leukemia. Biol Blood Marrow Transplant. 2012;18(6):930-936.
7. Brady KA, Atwater SK, Lowell CA. Flow cytometric detection of CD10 (cALLA) on peripheral blood B lymphocytes of neonates. Br J Haematol. 1999;107(4):712-715. (Pubitemid 30020140)
8. Longacre TA, Foucar K, Crago S, et al. Hematogones: a multiparameter analysis of bone marrow precursor cells. Blood. 1989;73(2):543-552. (Pubitemid 19060541)
9. Dreger P, Kloss M, Petersen B, et al. Autologous progenitor cell transplantation: prior exposure to stem cell-toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow grafts. Blood. 1995;86(10): 3970-3978.
10. Davies SM, Kollman C, Anasetti C, et al. Engraftment and survival after unrelated-donor bone marrow transplantation: a report from the national marrow donor program. Blood. 2000;96(13): 4096-4102.
11. Bensinger WI, Martin PJ, Storer B, et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Engl J Med. 2001;344(3):175-181. (Pubitemid 32064138)
12. Laughlin MJ, Barker J, Bambach B, et al. Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors. N Engl J Med. 2001;344(24):1815-1822. (Pubitemid 32538694)
13. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European Leukemia Net. Blood. 2010;115(3):453-474.
14. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89(6): 2079-2088. (Pubitemid 27132124)
15. Appelbaum FR, Anderson J. Allogeneic bone marrow transplantation for myelodysplastic syndrome: outcomes analysis according to IPSS score. Leukemia. 1998;12(Suppl 1):S25-S29. (Pubitemid 28479000)
16. Goldman JM, Schmitz N, Niethammer D, Gratwohl A. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe in 1998. Accreditation Sub-Committee of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 1998;21(1):1-7. (Pubitemid 28043429)
17. Perea G, Lasa A, Aventin A, et al. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. Leukemia. 2006; 20(1):87-94.
18. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25(5):579-586. (Pubitemid 350002966)
19. Uchida N, Wake A, Takagi S, et al. Umbilical cord blood transplantation after reduced-intensity conditioning for elderly patients with hematologic diseases. Biol Blood Marrow Transplant. 2008;14(5): 583-590. (Pubitemid 351494752)
20. Kim SW, Matsuo K, Fukuda T, et al. Reducedintensity unrelated donor bone marrow transplantation for hematologic malignancies. Int J Hematol. 2008;88(3):324-330.
21. Oda S, Oki E, Maehara Y, Sugimachi K. Precise assessment of microsatellite instability using high resolution fluorescent microsatellite analysis. Nucleic Acids Res. 1997;25(17):3415-3420. (Pubitemid 27359214)
22. Kikushige Y, Yoshimoto G, Miyamoto T, et al. Human Flt3 is expressed at the hematopoietic stem cell and the granulocyte/macrophage progenitor stages to maintain cell survival. J Immunol. 2008; 180(11):7358-7367.
23. Mori Y, Iwasaki H, Kohno K, et al. Identification of the human eosinophil lineage-committed progenitor: revision of phenotypic definition of the human common myeloid progenitor. J Exp Med. 2009; 206(1):183-193.
24. Imamura R, Miyamoto T, Yoshimoto G, et al. Mobilization of human lymphoid progenitors after treatment with granulocyte colony-stimulating factor. J Immunol. 2005;175(4):2647-2654. (Pubitemid 41113880)
25. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, et al. FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood. 2009;114(24):5034-5043.
26. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity. 1995;3(4):459-473.
27. LeBien TW. Fates of human B-cell precursors. Blood. 2000;96(1):9-23.
28. LeBien TW, Tedder TF. B lymphocytes: how they develop and function. Blood. 2008;112(5):1570-1580.
29. Yoshimoto G, Nagafuji K, Miyamoto T, et al. FLT3 mutations in normal karyotype acute myeloid leukemia in first complete remission treated with autologous peripheral blood stem cell transplantation. Bone Marrow Transplant. 2005;36(11):977-983. (Pubitemid 41741561)
30. Kikushige Y, Ishikawa F, Miyamoto T, et al. Selfrenewing hematopoietic stem cell is the primary target in pathogenesis of human chronic lymphocytic leukemia. Cancer Cell. 2011;20(2):246-259.
31. Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138(11):923-936. (Pubitemid 24002359)
32. Baron F, Sandmaier BM. Chimerism and outcomes after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Leukemia. 2006;20(10):1690-1700. (Pubitemid 44590958)
33. Matsuda K, Yamauchi K, Tozuka M, et al. Monitoring of hematopoietic chimerism by short tandem repeats, and the effect of CD selection on its sensitivity. Clin Chem. 2004;50(12):2411-2414. (Pubitemid 39552190)
34. Boeck S, Hamann M, Pihusch V, et al. Kinetics of dendritic cell chimerism and T cell chimerism in allogeneic hematopoietic stem cell recipients. Bone Marrow Transplant. 2006;37(1):57-64. (Pubitemid 43135316)
35. Laughlin MJ, Eapen M, Rubinstein P, et al. Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. N Engl J Med. 2004;351(22):2265-2275. (Pubitemid 39552742)
36. Rocha V, Labopin M, Sanz G, et al. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med. 2004;351(22):2276-2285. (Pubitemid 39552743)
37. Takahashi S, Iseki T, Ooi J, et al. Single-institute comparative analysis of unrelated bone marrow transplantation and cord blood transplantation for adult patients with hematologic malignancies. Blood. 2004;104(12):3813-3820. (Pubitemid 39564462)
38. Couban S, Simpson DR, Barnett MJ, et al. A randomized multicenter comparison of bone marrow and peripheral blood in recipients of matched sibling allogeneic transplants for myeloid malignancies. Blood. 2002;100(5):1525-1531. (Pubitemid 34925122)
39. Vigorito AC, Azevedo WM, Marques JF, et al. A randomised, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 1998;22(12):1145-1151. (Pubitemid 29021122)
40. Nunez C, Nishimoto N, Gartland GL, et al. B cells are generated throughout life in humans. J Immunol. 1996;156(2):866-872. (Pubitemid 26028949)
41. Rossi DJ, Bryder D, Zahn JM, et al. Cell intrinsic alterations underlie hematopoietic stem cell aging. Proc Natl Acad Sci U S A. 2005;102(26): 9194-9199. (Pubitemid 40923540)
42. Frasca D, Landin AM, Lechner SC, et al. Aging down-regulates the transcription factor E2A, activation-induced cytidine deaminase, and Ig class switch in human B cells. J Immunol. 2008; 180(8):5283-5290.
43. Allman D, Miller JP. The aging of early B-cell precursors. Immunol Rev. 2005;205:18-29. (Pubitemid 40780174)
44. Stem Cell Trialists' Collaborative Group. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol. 2005;23(22):5074-5087.
45. Shimabukuro-Vornhagen A, Hallek MJ, Storb RF, von Bergwelt-Baildon MS. The role of B cells in the pathogenesis of graft-versus-host disease. Blood. 2009;114(24):4919-4927.
46. Baker MB, Riley RL, Podack ER, Levy RB. Graftversus- host-disease- associated lymphoid hypoplasia and B cell dysfunction is dependent upon donor T cell-mediated Fas-ligand function, but not perforin function. Proc Natl Acad Sci U S A. 1997; 94(4):1366-1371.
47. Shono Y, Ueha S, Wang Y, et al. Bone marrow graft-versus-host disease: early destruction of hematopoietic niche after MHC-mismatched hematopoietic stem cell transplantation. Blood. 2010;115(26):5401-5411.
48. Miklos DB, Kim HT, Miller KH, et al. Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. Blood. 2005;105(7):2973-2978. (Pubitemid 40446295).